In Trading, Results Matter.
Our Top 10 exits in last 5 trading days.

AVEO Pharmaceuticals, Inc.. Trade Record

NASDAQ:AVEO AVEO Pharmaceuticals, Inc. stock gains 242.43% Exit Jul 17, 2017 a Trade Record by priceseries

Trade Chart
Trade Chart AVEO Jun 22, 2017, priceSeries
About AVEO Pharmaceuticals, Inc.

AVEO Pharmaceuticals, Inc., a biopharmaceutical company, develops targeted therapies for cancer and related diseases. The company's pipeline of product candidates include Tivozanib, a vascular endothelial growth factor (VEGF) to optimize VEGF blockade; Ficlatuzumab, a hepatocyte growth factor (HGF) inhibitory antibody, which has completed Phase II trial that inhibits the activity of the HGF/c-Met pathway; and AV-203, an anti-ErbB3 specific monoclonal antibody that has completed a Phase I dose escalation study. Its development programs also comprise AV-380, a humanized IgG1 inhibitory monoclonal antibody for the treatment or prevention of cachexia; and the AV-353 platform for the potential treatment of pulmonary arterial hypertension. The company has strategic partnerships with CANbridge Life Sciences Ltd.; EUSA Pharma (UK) Limited; Novartis International Pharmaceutical Ltd.; Biodesix, Inc.; St. Vincent's Hospital Sydney Limited; Biogen Idec International GmbH; and Kyowa Hakko Kirin Co., Ltd. The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was incorporated in 2001 and is based in Cambridge, Massachusetts.

Trade Information
Trade Type
Entry Date
Jun 22, 2017
Entry Price
Sell Date
Jul 17, 2017
Sell Price
Net Gain
Hold Time
16 Trading Days